UC San Francisco Plans to AeroNab the Virus

Google+ Pinterest LinkedIn Tumblr +

Graduate student Michael Schoof and his team at University of California in San Francisco have been thinking laterally. If the SARS-Cov-2 virus causing COVID-19 lurks in the upper nasal passages, they reason why don’t we zap it there? Moreover, UC San Francisco plans to AeroNab the virus just as soon as they have finished trials.

Inhaled Protection Behind UC San Francisco Plans to AeroNab Virus

The university media release says Michael Schoof’s team “engineered a completely synthetic, production-ready molecule”. And it adds it “straitjackets the crucial SARS-CoV-2 machinery that allows the virus to infect our cells”. Therefore, these UC San Francisco plans to AeroNab the virus certainly make sense to us!

After the research team placed an aerosol version in a nasal spray, they discovered how potent their molecule was. In fact, to quote the university media release it is “among the most potent SARS-CoV-2 antivirals yet discovered”. Moreover, they believe a single daily administration could outwit the virus pending the development of a vaccine.

Could Clinical Trials Lead to an Inexpensive Medical Stop Gap Soon?

The research team is confident the possibilities are there. That’s sufficiently confident to negotiate a manufacturing agreement before trialing and clinical approval. We should not be surprised to hear talk on campus of an inexpensive, over-the-counter medication. That’s a regular medicine able to prevent and treat COVID-19.

Peter Walter is professor of biochemistry and biophysics at University of California in San Francisco, and co-invented the antiviral molecule. He believes their radical invention will be “far more effective than wearable forms of personal protective equipment”.

He reports the tiny nano-molecules are exceptionally stable, and, we quote “they may help reshape the course of the pandemic worldwide”. Therefore, this UC San Francisco plan to AeroNab the virus sounds like one for the record books to us!

Related

U.S. Clinical Trials of Monoclonal Antibodies

Virally Vectored DNA versus mRNA Vaccines

Preview Image: The AeroNabs Nasal Spray

UC San Francisco Media Release

Share.

About Author

Electricity has always intrigued me. I have been writing about batteries and energy storage for more than ten years, and have published over 4,000 articles on this website. During that time, I have researched developments across lead-acid, lithium-ion, sodium-ion, flow batteries, and emerging energy-storage technologies. My goal is to explain complex battery concepts in clear, practical language that anyone can understand. My writing career began unexpectedly after leaving the corporate world. What started as a search for a new direction gradually became a fascination with batteries, renewable energy, and the science that powers modern life. Writing may not have made me wealthy, but it has given me the opportunity to explore an industry that continues to evolve in remarkable ways.

Leave A Reply